Skip to main content

Advertisement

Table 2 Whole genome sequencing

From: Whole genome sequencing reveals potential targets for therapy in patients with refractory KRASmutated metastatic colorectal cancer

Participant code Total reads sequenced Total bases sequenced Coverage Number of germline variants Percent dbSNP Transition/transversion ratio
CLN2 Normal 1.9 billion 200 Gb 50X 2.3 million 88% 2.05
CLN2 Tumor 1.4 billion 146 Gb 42X   
CLN3 Normal 2.0 billion 210 Gb 62X 3.4 million 88% 2.06
CLN3 Tumor 1.96 billion 204 Gb 40X   
CLN4 Normal 0.97 billion 100 Gb 28X 3.3 million 88% 2.06
CLN4 Tumor 1.03 billion 107 Gb 31X